LONDON—Rheumatologists need to make the management of psoriatic arthritis (PsA) “a little more complex,” treating different tissues individually and doing more to help treat and prevent co-morbidities, an expert said here at the Annual Congress of the European League Against Rheumatism (EULAR) 2016. Iain McInnes, MD, PhD, director of the Research Institute for Infection, Immunity…
Preclinical Phases of Rheumatoid Arthritis Better Understood
LONDON—Research continues to advance in understanding the causes, prediction and management of the stages of early arthritis before full-blown clinical disease, and an expert highlighted some of the latest of these encouraging findings at the Annual Congress of the European League Against Rheumatism (EULAR) 2016. Many of the genetic and environmental risk factors are known,…
Plasma Cells, Synovial Compartment Implicated in Tenacity of Rheumatoid Arthritis
LONDON—New research shows that the synovial compartment appears to have a special role in the chronic nature of rheumatoid arthritis (RA), providing refuge for plasma cells and giving them an ideal environment in which to produce antibodies against citrullinated protein antigens (ACPA). The findings were presented at the Annual Congress of the European League Against…
Diagnostic Criteria, Classification Lacking for Vasculitis; New Research in Treatment for Systemic Sclerosis
LONDON—Despite the detailed terminology for describing vasculitis established by the Chapel Hill Consensus (CHC) in 2012, the field badly needs better classification and diagnostic criteria for the group of diseases, an expert said in a presentation at the Annual Congress of the European League Against Rheumatism (EULAR 2016). It’s a topic that is now being…
Research on Ixekizumab in Psoriatic Arthritis and More Presented at EULAR 2016
LONDON—Results from the extension phase of a Phase 3 trial for the IL-17A inhibitor ixekizumab in psoriatic arthritis (PsA) show that patients started on placebo, adalimumab and ixekizumab continued to show improvements in arthritis, dactylitis and ethesitis, said Philip Mease, MD, a rheumatologist at Swedish Medical Center University of Washington in Seattle.1 Dr. Mease presented the…
Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment
LONDON—Josef Smolen, MD, chair of rheumatology at the University of Vienna and former president of the European League Against Rheumatism (EULAR), expressed a “personal disappointment” in the development of useful biomarkers in the treatment of rheumatoid arthritis (RA). Even though a good portion of his life’s work has been researching biomarkers to help with targeting…
New Research into Rheumatoid Arthritis, Gout Includes Updates on Methotrexate, Biologics, Ultrasound
LONDON—From optimizing responses to methotrexate, to the efficacy of biologics, to the need for imaging in assessing remission, the literature, as ever, has been lively with explorations of pressing topics in the treatment and management of rheumatoid arthritis. Josef Smolen, MD, chair of rheumatology at the Medical University of Vienna, reviewed many of the highlights…
Potential Benefits, Pitfalls of Biosimilars Reviewed at EULAR 2016
LONDON—The availability of a biosimilar form of infliximab has dramatically increased the number of Norwegians taking one form or another of the drug, an expert on biosimilars said in a debate-style session at the Annual Congress of the European League Against Rheumatism (EULAR 2016). The expanded uptake of Remicade (infliximab) and its biosimilar, Remsima (international…
The ACR’s Collaboration with International Rheumatology Associations Promotes Progress
More than 10 years ago, New York Times journalist Thomas Friedman opined an old-world perspective that the world is, in fact, flat. In an article published on April 3, 2005, Mr. Friedman contended that “Individuals must, and can, now ask: Where do I fit into the global competition and opportunities of the day, and how…
New Gout Criteria from the ACR/EULAR Focus on Clinical Trials, Global Standards
Gout affects nearly 4% of American adults, causing joint inflammation, pain and crystal deposits that may lead to bone erosion over time. At least five different classification criteria for gout are used worldwide, creating potential discrepancies in clinical trial enrollment and eventual results. An international panel of investigators collaborated to create new, standardized gout classification…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 16
- Next Page »